poisar

Stocks · News reference

GeneDx Partners With Beren Therapeutics To Launch The NPC GenomeComplete Sponsored Testing Program For Niemann-Pick Disease Type C

BenzingaBenzinga Newsdesk

The program provides no-cost comprehensive genome sequencing for eligible pediatric patients with clinical findings, family history, or biomarker evidence suggestive of Niemann-Pick Disease Type C (NPC), helping address

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading